

Priority Research Programme

Foods for improving gut function and comfort

HIGH-VALUE
NUTRITION

Ko Ngā Kai
Whai Painga

Biomarkers for gut comfort

Karl Fraser

Senior Scientist, Metabolomics

AgResearch


Host Institution



High-Value Nutrition National Science Challenge research themes and projects

- TOFI: Thin on the outside, fat inside: preventing diabetes
- Kiwifruit for glucose control
- Combined proteins for lean body mass
- Grass-fed beef for cholesterol control

- Complementary feeding for immune protection
- Fibres for sustained energy release




- Building immune defence
- Natural milk for allergy management
- Greenshell™ mussels to manage inflamed joints

- Foods for gut function and comfort
- A2 Milk for gut comfort

Irritable Bowel Syndrome is the ideal model for developing future foods with clinical evidence to support claims for healthy people

Heathy gut for a healthy body



- Diet impacts more than just gut health
- Gut plays a central role
- **Foods for gut function and comfort critical to health**

Vernocchi et al (2016). *Frontiers in Microbiology* 7:1144.

Biomarkers

- “A characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes or pharmacologic responses to a therapeutic intervention”¹
- Assess digestive health² using models of suboptimal function and comfort such as irritable bowel syndrome (IBS)
 - Subjective assessments, e.g. questionnaires and gut symptom scores
 - Objective gut parameters such as: functionality, integrity, markers of immunity, microbiome, etc.
- Can define phenotypes
- Multiple approaches and measures enhance accuracy

[1] de Vries *et al* (2013). Markers for nutrition studies: review of criteria for the evaluation of markers. *Eur J Nutr.* 52:1685–1699

[2] Bischoff (2011). ‘Gut Health’: a new objective in medicine?. *BMC Med.* 9:24

A biomarker panel and psychological morbidity differentiates the irritable bowel syndrome from health and provides novel pathophysiological leads


M. P. Jones^{*}, W. D. Chey[†], S. Singh[‡], H. Gong[‡], R. Shringarpure[‡], N. Hoe[‡], E. Chuang[‡] & N. J. Talley[§]

34 biomarkers and 4 psychological tools

- Inflammatory cytokines and chemokines
- Gene expression markers
- Growth factors
- Microbial antibodies
- Molecular transporters
- Markers of histamine activation
- Neurotransmitters
- Gut hormones

→ Phenotyping is not defining mechanisms




→ Needs an integrated systems approach




The full panel of biomarkers in combination with psychological measures provides strong overall differentiation of IBS cases from healthy volunteers (AUC = 0.93).

- 60 IBS constipation
- 57 IBS diarrhoea
- 51 IBS mixed
- 76 Healthy controls

Metabolomics – biomarker discovery



The metabolite concentration 'iceberg'




- Wide concentration range of metabolites (mM to <pM)
- Critical metabolites can occur at low concentrations e.g. hormones

✓ **Mass spectrometry gives greatest coverage of the metabolome**

Plasma profiling the COMFORT cohort sample set to date


- 102 plasma samples extracted
 - 36 healthy controls
 - 24 with constipation = 17 Functional Constipation (FC) + 7 IBS-C
 - 22 with diarrhoea = 4 Functional Diarrhoea (FD) + 18 IBS-D
 - 12 with mixed symptoms (IBS-M)
 - 8 not yet diagnosed (awaiting survey data)

Multiple analytical streams







✓ Majority of plasma metabolome measured

Data collection is only the beginning...






Can we differentiate IBS from a healthy gut?



- PLS-DA of polar metabolites can (shown here)
- Similar results for semi-polar and lipid analyses
- Models show discrimination between groups
- ✓ **More samples will improve differentiation**


What are the metabolic drivers?

Example – Healthy gut vs IBS-D



- Differentiation observed across the metabolome
- What are the key features driving separation?



Polar metabolite network: reveal key 'hubs'




[1] Mujagic *et al* (2016). A novel biomarker panel for IBS. *Sci Rep.* 6:26420

Pathway mapping can reveal new targets

- Perturbations in bile acid metabolism – elevated in IBS-D
- Pathway mapping can imply further targets for analysis (underway)




Ursodeoxycholic acid



Targeted analysis of key pathways - bile acids

- Previous studies have implicated bile acid dysbiosis¹
- Targeted method developed and implemented at AgResearch with collaborators (APC, Ireland)







- Initial results show potential (see poster)

[1] Camilleri *et al* (2015). Bile acid diarrhea. *Gut and Liver* 9(3): 332–339.

Major perturbations in lipidome

→ Altered phospholipid metabolism

Phosphoethanolamine



→ Higher plasma triacylglycerols

Lipid metabolism: interactions within the host

- Gut microbiome can impact host lipid levels¹:
 - Gut microbe associations with bile acid composition and plasma lipid levels
 - Short-chain fatty acid production and absorption impacts host energy metabolism
 - Bacterial intermediates further metabolised by host – possible effects on lipid levels

[1] Allayee and Hazen (2016). Contribution of Gut Bacteria to Lipid Levels. *Circ Res.* 117(9):750-754

Conclusions

- Metabolomics provides both phenotypic and mechanistic information
 - Reinforces need for multi-omics approach to understand mechanisms at system level
 - Increasing the COMFORT cohort size will improve predictive power to enhance the systems approach
- *Clinical and systems approach will de-risk developing new foods with validated gut health benefits that will be highly desirable and sought after by healthy consumers*

Acknowledgements

Programme Leader/Principal Investigator

- Nicole Roy, AgResearch

Principal Investigator, clinical

- Richard Garry, University of Otago
 - Phoebe Heenan, Shriya Sharma

Associate Investigators, biomarkers

- Metabolites: Karl Fraser, AgResearch
 - Hedley Stirrat, Heike Schwendel
- Microbiota: Wayne Young, AgResearch
- Immune: Oliver Grasser, Malaghan Institute
- Proteins: Janine Cooney, Plant and Food Research

Collaborators

- Pathway Analysis: Jean-Charles Martin, INRA, BIOMET, University of Marseille, France
- Bile acids: Susan Joyce, APC Microbiome Institute, Ireland



HIGH-VALUE
NUTRITION

Ko Ngā Kai
Whai Painga